dl-(4S,5S)-1-(4-fluorophenyl)-4-methyl-2-phenyl-4,5-dihydro-1H-imidazole-4,5-dicarboxylic acid 5-ethyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: dl-(4S,5S)-1-(4-fluorophenyl)-4-methyl-2-phenyl-4,5-dihydro-1H-imidazole-4,5-dicarboxylic acid 5-ethyl ester
• 英文别名: dl-(4S, 5S)-1-(4-fluorophenyl)-2,4-diphenyl-4,5-dihydro-1H-imidazole-4,5-dicarboxylic acid 5-ethyl ester；Dl-(3S,4S)-1-(4-fluorophenyl)-4-methyl-2-phenyl-4,5-dihydro-1H-imidazole-4,5-dicarboxylic acid 5-ethyl ester；(4R,5S)-4-ethoxycarbonyl-3-(4-fluorophenyl)-5-methyl-2-phenyl-4H-imidazole-5-carboxylic acid
• 化学式: C₂₀H₁₉FN₂O₄
• 分子量: 370.38
• InChiKey: ZODTUMOSUFZJBL-JXFKEZNVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  乙醛酸乙酯 、 4-甲基-2-苯基-2-噁唑啉-5-酮 、 4-氟苯胺 在 三甲基氯硅烷 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 2.0h， 以72%的产率得到dl-(4S,5S)-1-(4-fluorophenyl)-4-methyl-2-phenyl-4,5-dihydro-1H-imidazole-4,5-dicarboxylic acid 5-ethyl ester
  参考文献：
  名称：

  NF-kB inhibitors and uses threreof

  摘要：

  描述了一类新型的咪唑啉化合物，作为4-位置酸或酯具有非常强大的抗炎和抗菌活性。这些咪唑啉的合成包括一种适用于组合合成方法的多组分反应。这两个关键特性的结合提供了一种有效的治疗药物，可用于治疗败血症休克以及许多其他炎症（如关节炎和哮喘）和传染性疾病。描述了这一新型非甾体类抗炎药物（用于治疗哮喘等）、抗菌药物和防腐剂的用途。这些化合物还可用于治疗肿瘤（如癌症）。咪唑啉是转录因子NF-κB的强效抑制剂，对革兰氏阳性细菌也具有强效活性。这些组合物还可用于治疗自身免疫性疾病，并抑制器官和组织移植的排斥。

  公开号：

  US20030232998A1

文献信息

• Multi-substituted imidazolines and method of use thereof
  申请人：Board of Trustees of MICHIGAN STATE UNIVERSITY

  公开号：US20030232870A1

  公开（公告）日：2003-12-18

  A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-&kgr;B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 &mgr;m/mL.

  描述了一类新型的咪唑啉，作为4位酸或酯，具有非常强大的抗炎和抗微生物活性。这些咪唑啉的合成包括适用于组合合成方法的多组分反应。这两个关键特性的结合提供了一种有效的治疗药物，可用于治疗脓毒性休克以及许多其他炎症（关节炎和哮喘）和传染性疾病。描述了这种新型非甾体类抗炎药物（用于哮喘等的治疗）、抗菌药物和防腐剂的用途。这些化合物还可用于肿瘤的治疗（如癌症）。咪唑啉是转录因子NF-κB的强效抑制剂，并对革兰氏阳性细菌B. subtillus和B. cereus具有强大的活性，MIC值在50 μm/mL的范围内。
• NF-kB inhibitors and uses thereof
  申请人：Tepe Jetze J.

  公开号：US20080114015A1

  公开（公告）日：2008-05-15

  A diastereomers of imidazolines as 4-position acids are described. The imidazoline diastereomers potentiate the activity of antitumor drugs and are potent inhibitors of the transcription factor NF-κB.
• NF- kB Inhibitors And Uses Thereof
  申请人：Tepe Jetze J.

  公开号：US20090275603A1

  公开（公告）日：2009-11-05

  A new class of imidazolines as 4-position esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.
• US7858808B2
  申请人：——

  公开号：US7858808B2

  公开（公告）日：2010-12-28
• US8552206B2
  申请人：——

  公开号：US8552206B2

  公开（公告）日：2013-10-08